Could a diabetes pill protect kidneys in lupus patients?
NCT ID NCT07323524
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether dapagliflozin, a drug already used for diabetes and other kidney diseases, can help people with lupus nephritis. About 33 adults with active lupus kidney inflammation will receive either dapagliflozin or a placebo alongside their usual treatment. The main goal is to see if it's feasible to run a larger trial, not yet to prove the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin
What this could lead to
If it works, this could point toward a new way to protect kidneys in people with lupus nephritis, reducing the risk of kidney failure.
What could go wrong
This is a small pilot study with only 33 people, so results may not apply broadly. It's testing feasibility, not yet proven to work, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••